Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lianbio ADR
(NQ:
LIAN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lianbio ADR
< Previous
1
2
3
4
Next >
Dow Surges 250 Points; US Manufacturing PMI Tops Expectations
October 24, 2023
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 250 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.80% to 33,200.75 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 24, 2023
Via
Benzinga
LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets
October 24, 2023
From
LianBio
Via
GlobeNewswire
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
August 28, 2023
From
LianBio
Via
GlobeNewswire
LianBio: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
LianBio
Via
GlobeNewswire
Week In Review: Mundipharma Considers $1 Billion Sale Of China Operations
August 05, 2023
Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize...
Via
Talk Markets
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
August 03, 2023
From
LianBio
Via
GlobeNewswire
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis
July 26, 2023
From
LianBio
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 26, 2023
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all the latest news this morning!
Via
InvestorPlace
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand
July 18, 2023
From
LianBio
Via
GlobeNewswire
LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023
July 17, 2023
From
LianBio
Via
GlobeNewswire
LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
July 12, 2023
From
LianBio
Via
GlobeNewswire
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore
June 26, 2023
From
LianBio
Via
GlobeNewswire
LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
June 08, 2023
From
LianBio
Via
GlobeNewswire
LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China
June 06, 2023
From
LianBio
Via
GlobeNewswire
LianBio to Participate in Upcoming Investor Conferences
June 01, 2023
From
LianBio
Via
GlobeNewswire
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....
Via
Talk Markets
LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
LianBio
Via
GlobeNewswire
LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China
May 11, 2023
From
LianBio
Via
GlobeNewswire
LianBio Touts Positive Data From Bristol Myers-Partnered Heart Drug In Chinese Patients
April 26, 2023
LianBio (NASDAQ: LIAN) announced
Via
Benzinga
LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients
April 26, 2023
From
LianBio
Via
GlobeNewswire
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 27, 2023
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its...
Via
Benzinga
LianBio Promotes Pascal Qian to Chief Commercial Officer
April 21, 2023
From
LianBio
Via
GlobeNewswire
LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
April 21, 2023
From
LianBio
Via
GlobeNewswire
LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 27, 2023
From
LianBio
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 21, 2023
Via
Benzinga
Pfizer Opts In To LianBio Rights to Respiratory Syncytial Virus Candidate In Greater China
December 19, 2022
Via
Benzinga
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 12, 2023
Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity...
Via
Benzinga
Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore
December 19, 2022
From
LianBio; Pfizer Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.